Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated?
Direct-to-consumer advertising is banned in Australia, and instead pharmaceutical companies use disease awareness campaigns as a strategy to raise public awareness of conditions for which the company produces a treatment. This practice has been justified by promoting individual autonomy and public h...
| Autores principales: | ; |
|---|---|
| Tipo de documento: | Electrónico Artículo |
| Lenguaje: | Inglés |
| Verificar disponibilidad: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Publicado: |
2018
|
| En: |
Journal of medical ethics
Año: 2018, Volumen: 44, Número: 9, Páginas: 621-625 |
| Acceso en línea: |
Volltext (JSTOR) Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1816158526 | ||
| 003 | DE-627 | ||
| 005 | 20230428063503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2017-104504 |2 doi | |
| 035 | |a (DE-627)1816158526 | ||
| 035 | |a (DE-599)KXP1816158526 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Benson, Stuart |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Is there a nocebo response that results from disease awareness campaigns and advertising in Australia, and can this effect be mitigated? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Direct-to-consumer advertising is banned in Australia, and instead pharmaceutical companies use disease awareness campaigns as a strategy to raise public awareness of conditions for which the company produces a treatment. This practice has been justified by promoting individual autonomy and public health, but it has attracted criticism regarding medicalisation of normal health and ageing, and exaggeration of the severity of the condition in question, imbalanced reporting of risks and benefits, and damaging the patient-clinician relationship. While there are benefits of disease awareness promotion, there is another possible adverse consequence that has not yet been rigorously considered: the possibility of inducing a nocebo response via the campaign. We will discuss the creation of a nocebo response in this context. | ||
| 700 | 1 | |a Hunter, David |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 44(2018), 9, Seite 621-625 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnas |
| 773 | 1 | 8 | |g volume:44 |g year:2018 |g number:9 |g pages:621-625 |
| 856 | |3 Volltext |u http://www.jstor.org/stable/26879806 |x JSTOR | ||
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2017-104504 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://jme.bmj.com/content/44/9/621.abstract |x Verlag |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 418561246X | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1816158526 | ||
| LOK | |0 005 20220908053725 | ||
| LOK | |0 008 220908||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-08-03#17EF3F577C6C87228D0D96B50C6BFAA6A07121A0 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 866 |x JSTOR#http://www.jstor.org/stable/26879806 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 |b inherited from superior work | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||
